Cellectar Biosciences, Inc. announced a new licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for intellectual property that was the result of collaborative research conducted at the University of Wisconsin-Madison (UW) with iopofosine I 131 in pediatric cancers. Under the terms of the agreement, Cellectar has an exclusive license to develop and commercialize iopofosine in various pediatric solid cancers, such as high-grade glioma, neuroblastoma and sarcoma.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.39 USD | -0.88% | +10.32% | +23.47% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.47% | 123M | |
+28.50% | 662B | |
+22.23% | 546B | |
-4.93% | 359B | |
+16.97% | 323B | |
+4.08% | 289B | |
+13.68% | 234B | |
+3.84% | 198B | |
-10.35% | 194B | |
+3.98% | 167B |
- Stock Market
- Equities
- CLRB Stock
- News Cellectar Biosciences, Inc.
- Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation